Expression and correlation of CD44V4 and nm23 in triple negative breast cancer
LI Jun1 LI Chunying2
1.Department of Breast Hernia Surgery, Liuzhou Municipal Liutie Central Hospital, Guangxi Zhuang Autonomus Region, Liuzhou 545007, China;
2.Department of Pathology, Liuzhou Municipal Liutie Central Hospital, Guangxi Zhuang Autonomus Region, Liuzhou 545007, China
Abstract：Objective To explore the expression of CD44V4 and nm23 in triple negative breast cancer (TNBC) and their correlation in clinical prognosis. Methods Seventy TNBC patients admitted to Department of General Surgery, Liuzhou Municipal Liutie Central Hospital Guangxi Zhuang Autonomous Region (hereinafter referred to as "our hospital") from January 2010 to March 2015 were selected as the study group, and 70 non-TNBC patients in the same period in our hospital were selected as the control group. Immunohistochemistry was used to detect the expression of CD44V4 and nm23 in the cancer tissues of patients of two groups, and their correlation in the poor prognosis of TNBC was analyzed. Results The positive expression rate of CD44V4 in the study group was significantly higher than that in the control group, and the positive expression rate of nm23 in the study group was significantly lower than that in the control group. The differences were statistically significant (all P ＜ 0.05). The positive expression of CD44V4 in TNBC patients was correlated with vascular infiltration and lymph node metastasis (P < 0.05). The positive expression of nm23 was associated with lymph node metastasis (P ＜ 0.05). There was no significant correlation between CD44V4 and nm23 expression in TNBC cancer tissues (rs = -0.166, P ＞ 0.05). Conclusion The positive expression of CD44V4 in TNBC was up-regulated, while the positive expression of nm23 was down-regulated. The detection of the relationship between CD44V4, nm23 in TNBC and invasion, metastasis is of great value, and may become a new biomarker to judge the prognosis of TNBC.
李俊1 李春英2. CD44V4和nm23在三阴性乳腺癌中的表达及其相关性[J]. 中国医药导报, 2019, 16(29): 100-103.
LI Jun1 LI Chunying2. Expression and correlation of CD44V4 and nm23 in triple negative breast cancer. 中国医药导报, 2019, 16(29): 100-103.
[1] Khosravi-Shahi P，Cabezón-Gutiérrez L，Custodio-Cabello S. Metastatic triple negative breast cancer：Optimizing treatment options，new and emerging targeted therapies [J]. Asia Pac J Clin Oncol，2018，14（1）：32-39.
[2] Jhan JR，Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy [J]. Pharmacogenomics，2017，18（17）：1595-1609.
[3] Athanassiou-Papaefthymiou M，Shkeir O，Kim D，et al. Evaluation of CD44 variant expression in oral，head and neck squamous cell carcinomas using a triple approach and its clinical significance [J]. Int J Immunopathol Pharmacol，2014，27（3）：337-349.
[4] 李键淇，齐洁敏.整合素α2β1及CD44v4在胃癌组织中的表达及意义[J].中国老年学杂志，2017，37（4）：910-912.
[5] Liu L，Li M，Zhang C，et al. Prognostic value and clinicopathologic significance of nm23 in various cancers： A systematic review and meta-analysis [J]. Int J Surg，2018， 60：257-265.
[6] Han W，Zhang C，Cao FY，et al. Prognostic and clinicopathological value of NM23 expression in patients with?breast cancer：A systematic review and meta-analysis [J]. Curr Probl Cancer，2017，41（1）：80-93.
[7] 中国抗癌协会乳腺癌专业委员会.《中国抗癌协会乳腺癌诊治指南与规范（2017年版）》 [J].中国癌症杂志，2017， 27（9）：695-759.
[8] Ma Y，Zhang S，Zang L，et al. Combination of shear wave elastogra-phy and Ki －67 index as a novel predictive modality for the patho-logical response to neoadjuvant chemotherapy in patients with inva-sive breast cancer [J]. Eur J Cancer，2016，69：86-101.
[9] Nie M，Qin Y，Zhu J，et al. Correlation between ultrasonic features and expression levels of C-erbB-2，VEGF and nm23 in breast cancer [J]. Oncol Lett，2018，16（2）：1701-1707.
[10] Chas M，Boivin L，Arbion F，et al. Clinicopathologic predictors of lymph node metastasis in breast cancer patients according to molec-ular subtype [J]. J Gynecol Obstet Hum Ｒeprod，2018，47（1）：9-15.
[11] Jang MH，Kim HJ，Gwak JM，et al. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer [J]. Hum Pathol 2017，68：69-78.
[12] Mouh FZ，Mzibri ME，Slaoui M，et al. Recent Progress in Triple Negative Breast Cancer Research [J]. Asian Pac J Cancer Prev，2016，17（4）：1595-1608.
[13] Kashyap T，Pramanik KK，Nath N，et al. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance，invasion/migration and stemness via expression of CD44 variants （v4 and v6） in oral cancer [J]. Oral Oncol，2018，86：234-243.
[14] Geng Y，Chandrasekaran S，Hsu JW，et al. Phenotypic switch in blood： effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion [J]. PLoS One，2013， 8（1）：e54959.
[15] Koz?覥owski J，Koz?覥owska A，Kocki J. Breast cancer metastasis-insight into selected molecular mechanisms of the phenomenon [J]. Postepy Hig Med Dosw(Online)，2015， 69：447-451.
[16] Zen K，Liu DQ，Guo YL，et al. CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration [J]. PLoS One，2008，3（3）：e1826.
[17] Iqbal B，Masood A，Lone MM，et al. Polymorphism of Metastasis Suppressor Genes MKK4 and NME1 in Kashmiri Patients with Breast Cancer [J]. Breast J，2016，22（6）：673-677.
[18] Tan CY，Chang CL. NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma [J]. Lab Invest，2018，98（2）：219-227.
[19] Okabe-Kado J，Hagiwara-Watanabe Y，Niitsu N，et al. NM23 downregulation and lysophosphatidic acid receptor EDG2/lpa1 upregulation during myeloid differentiation of human leukemia cells [J]. Leuk Res，2018，66：39-48.
[20] Zhou YH，Liao SJ，Li D，et al. TLR4 ligand/H?O? enhances TGF-β1 signaling to induce metastatic potential of non-invasive breast cancer cells by activating non-Smad pathways [J]. PLoS One，2013，8（5）：e65906.
2019, Vol. 16 
京公网安备 11010502046598号